uniblue a has been researched along with reactive red 2 in 1 studies
| Studies (uniblue a) | Trials (uniblue a) | Recent Studies (post-2010) (uniblue a) | Studies (reactive red 2) | Trials (reactive red 2) | Recent Studies (post-2010) (reactive red 2) |
|---|---|---|---|---|---|
| 8 | 0 | 4 | 64 | 0 | 27 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bültmann, R; Starke, K; Trendelenburg, M; Tuluc, F; Wittenburg, H | 1 |
1 other study(ies) available for uniblue a and reactive red 2
| Article | Year |
|---|---|
Concomitant blockade of P2X-receptors and ecto-nucleotidases by P2-receptor antagonists: functional consequences in rat vas deferens.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Anthraquinones; Evans Blue; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Naphthalenes; Naphthalenesulfonates; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Rats, Wistar; Receptors, Purinergic P2X; Sensitivity and Specificity; Sulfonic Acids; Suramin; Triazines; Trypan Blue; Vas Deferens | 1999 |